Fig. 1

Thymosin beta 10 (TMSB10) is upregulated in breast cancer. a TMSB10, prothymosin, alpha (PTMA), parathymosin (PTMS), TMSB4X, TMSB15A and TMSB15B expression was upregulated to varying degrees in the RNA sequencing profile of breast cancer of the E-GEOD-58135 dataset. b and c Expression of TMSB10 was upregulated in breast cancer tissues and breast cancer cells compared with normal breast tissue samples and epithelium cells in the E-GEOD-58135 and E-GEOD-3744 profiles, respectively. Each bar represents the median values ± quartile values. d and e Real-time PCR and western blotting analysis of TMSB10 expression in NMEC1, NMEC2 and breast cancer cell lines. Glyceraldehyde-3-phosphate dehydrogenase was used as endogenous control in RT-PCR and α-Tubulin was detected as a loading control in the western blot. Each bar represents the mean values ± SD of three independent experiments. *P < 0.05. f and g mRNA and protein expression levels of TMSB10 in nine paired breast cancer tissue samples. The average TMSB10 mRNA expression level was normalized to the expression of GDPDH. α-Tubulin was detected as a loading control. Each bar represents the mean values ± SD of three independent experiments. *P < 0.05. h The average expression level of TMSB10 in patients with breast cancer with gains (amplification) was higher than those without gains in The Cancer Genome Atlas (TCGA) breast cancer dataset. Each bar represents the median values ± quartile values. i Change in copy number of TMSB10 due to gains in nine paired patients with breast cancer. Each bar represents the mean values ± SE. j Average expression level of TMSB10 in patients with breast cancer with gains was higher than those without gains in our breast cancer tissues. Each bar represents the median values ± quartile values. BRCA Breast cancer gene 1, ANT Adjacent normal tissue, T Tumor